Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2011 Feb 1;17(3):393-5. doi: 10.1158/1078-0432.CCR-10-2925. Epub 2011 Jan 25.

Response to combined molecular targeting: defining the role of P-STAT3.

Author information

  • 1Department of Otolaryngology and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Abstract

Src family kinase (SFK)-targeting agents are currently undergoing clinical investigation for treatment of solid malignancies. Epidermal growth factor receptor (EGFR)-independent phosphorylation of STAT3 (P-STAT3) has been identified as a mechanism of tumor resistance to agents targeting SFK. Tumor P-STAT3 levels may be an important indicator of EGFR- and SKF-targeted antitumor treatment efficacy.

©2010 AACR.

Comment on

PMID:
21266530
[PubMed - indexed for MEDLINE]
PMCID:
PMC3149866
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk